Amgen Psoriasis Candidate Impresses

Posted on April 04, 2012 at 18:15 PM EDT

The New England Journal of Medicine recently published positive phase II data on Amgen’s (NASDAQ:AMGN) psoriasis candidate, brodalumab (formerly known as AMG 827). Results from the 12-week randomized, double-blind, placebo-controlled, dose-ranging phase II study, conducted with 198 patients suffering from moderate-to-severe plaque psoriasis, showed that brodalumab achieved its primary endpoint. The mean percentage improvement in [...]

The New England Journal of Medicine recently published positive phase II data on Amgen’s (NASDAQ:AMGN) psoriasis candidate, brodalumab (formerly known as AMG 827).
Results from the 12-week randomized, double-blind, placebo-controlled, dose-ranging phase II study, conducted with 198 patients suffering from moderate-to-severe plaque psoriasis, showed that brodalumab achieved its primary endpoint. The mean percentage improvement in psoriasis area and severity index (PASI) was higher in all brodalumab … [visit site to read more] or compare Credit Card Rewards and Best Credit Cards

Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Telekurs USA
Postage Rates